Regulation of Hormone Resistant Breast Cancer by IGF and Insulin System Signaling Both effective and tolerable, hormonal agents such as tamoxifen and aromatase inhibitors have had a profound Impact on the treatment of estrogen receptor positive (ER""""""""^) breast cancer in the adjuvant and metastatic setting. ER+ breast cancers represent the majority of all breast cancer. However, both primary and acquired resistance to these agents is common and developing new methods to overcome or prevent resistance would have a major impact in breast cancer. Insulin-like growth factor (IGF) signaling has been implicated as a major resistance pathway to therapies directed at the ER through the activation of two membrane receptor tyrosine kinases: 1) IGF-I receptor (IGF-IR) through binding in IGF-I and IGF-II and the 2) InsR Isoform A (InsR-A) through binding of IGF-II. We now demonstrate evidence that complete blockade of both IGF signaling receptors with a tyrosine kinase inhibitor (BMS-754807) is sufficient to reverse resistance to hormonal therapy in vivo. In contrast, IGF-IR inhibition alone did not induce regression and led to upregulation of InsR-A Isoforms. It is unclear if the metabolic isoform of the InsR (InsR-B), which binds Ins, but not IGF-I or IGF-II is important to proliferation and survival signaling in hormonal therapy resistance. This question is important, as BMS-754807 inhibits both InsR isoforms in addition to IGF-IR and may have potential metabolic liabilities of blocking the action of Ins on InsR-B. However, it is also plausible that Ins signaling blockade is important to reversal of hormone therapy resistance. Our overarching goal is to determine which IGF/Ins signaling components are necessary for this effect. We hypothesize that IGF blockade is sufficient to overcome hormonal therapy resistance in vivo in multiple models, has less potential to upregulate alternative signaling mechanisms and will be tolerable at effective doses in breast cancer patients. To test these hypotheses, we propose to: 1) optimize BMS-754807 combinations in hormonal therapy resistant models, 2) determine if Ins and/or InsR-A signaling is sufficient for IGF-IR-independent resistance to homrional therapy and 3) evaluate the efficacy of BMS-754807 and letrozole and perform correlative studies in patients with breast cancer.

Public Health Relevance

Resistance to hormonal therapies in breast cancer represents a clinically unmet need. Should IGF/Ins blockade enhance the activity of hormonal therapies and reverse or prevent the acquisition of resistance, this could have a major impact. Possible outcomes include co-IGF/hormonal blockade Increasing survival in metastatic breast cancer and increasing the rate of cure in the adjuvant setting.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA116201-08
Application #
8744906
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Project Start
2013-09-01
Project End
2016-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
8
Fiscal Year
2013
Total Cost
$332,926
Indirect Cost
$101,763
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Qin, Sisi; Ingle, James N; Liu, Mohan et al. (2017) Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion. Breast Cancer Res 19:95
Athreya, Arjun P; Kalari, Krishna R; Cairns, Junmei et al. (2017) Model-based unsupervised learning informs metformin-induced cell-migration inhibition through an AMPK-independent mechanism in breast cancer. Oncotarget 8:27199-27215
Leon-Ferre, Roberto A; Polley, Mei-Yin; Liu, Heshan et al. (2017) Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat :
Fagerholm, Rainer; Khan, Sofia; Schmidt, Marjanka K et al. (2017) TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer. Oncotarget 8:18381-18398
Weinshilboum, Richard M; Wang, Liewei (2017) Pharmacogenomics: Precision Medicine and Drug Response. Mayo Clin Proc 92:1711-1722
Amos, Christopher I; Dennis, Joe; Wang, Zhaoming et al. (2017) The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. Cancer Epidemiol Biomarkers Prev 26:126-135
Engmann, Natalie J; Scott, Christopher G; Jensen, Matthew R et al. (2017) Longitudinal Changes in Volumetric Breast Density with Tamoxifen and Aromatase Inhibitors. Cancer Epidemiol Biomarkers Prev 26:930-937
Vierkant, Robert A; Degnim, Amy C; Radisky, Derek C et al. (2017) Mammographic breast density and risk of breast cancer in women with atypical hyperplasia: an observational cohort study from the Mayo Clinic Benign Breast Disease (BBD) cohort. BMC Cancer 17:84
Yaghjyan, Lusine; Stoll, Ethan; Ghosh, Karthik et al. (2017) Tissue-based associations of mammographic breast density with breast stem cell markers. Breast Cancer Res 19:100
Couch, Fergus J; Shimelis, Hermela; Hu, Chunling et al. (2017) Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. JAMA Oncol 3:1190-1196

Showing the most recent 10 out of 428 publications